PremiumThe FlyPalvella Therapeutics expects cash to fund operations into H2 of 2027 Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics Palvella Therapeutics granted U.S patent for QTORIN Rapamycin PremiumRatingsHigh-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald Palvella Therapeutics Reports 2024 Financial Results and Updates PremiumRatingsPositive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential Palvella Therapeutics initiated with an Outperform at Scotiabank Palvella Therapeutics Enhances Investor Relations with New Presentation 
